Conferences - Results from #9680

GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD, et al. - Slide Presentation February 19, 2013

GU Cancers Symposium 2013 - GTx-758, an ERα agonist, reduces serum free testosterone and serum PSA in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster February 19, 2013

GU Cancers Symposium 2013 - Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer: Immune results, by Emmanuel S. Antonarakis, MD, et al February 19, 2013

GU Cancers Symposium 2013 - Immune response to sipuleucel-T in patients with metastatic castrate-resistant prostate cancer (mCRPC): Phase 2 ProACT study, by Thomas A. Gardner, MD, et al. - Poster February 19, 2013

GU Cancers Symposium 2013 - Sipuleucel-T delayed time to first use of opioid analgesics in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in the IMPACT trial, by Eric J. Small, MD, et al. - Poster February 19, 2013

GU Cancers Symposium 2013 - Real-world experience with sipuleucel-T in metastatic castration-resistant prostate cancer patients ≥ 80 years-old: Data from PROCEED, by A. Oliver Sartor, MD, et al. - Poster February 19, 2013

GU Cancers Symposium 2013 - Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor, by Howard I. Scher, MD - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - Updated interim analysis of COU-AA-302, a randomized phase III study of abiraterone acetate in patients with metastatic castration-resistant prostate cancer without prior chemotherapy, by D. E. Rathkopf, MD - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up, Andrew Loblaw, MD, FRCPC, MSc - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - Novel strategies for targeting the androgen-receptor axis: PARP1 as a mediator of androgen receptor-dependent transcriptional control, by Karen E. Knudsen, PhD - Session Highlights February 15, 2013

GU Cancers Symposium 2013 - Clinical trial design strategies in the post-abiraterone/enzalutamide setting, by Charles J. Ryan, MD, UCSF - Session Highlights February 15, 2013

GU Cancers Symposium 2013 - What tools are available to aid in the use of active surveillance? The imaging perspective - Session Highlights February 15, 2013

GU Cancers Symposium 2013 - High-risk prostate cancer treated with pelvic radiotherapy and 36 vs 18 months of androgen blockade: Results of a phase III randomized trial - Slide Presentation February 15, 2013

GU Cancers Symposium 2013 - Updated analysis of radium-223 dichloride impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 randomized trial (ALSYMPCA) - Poster February 15, 2013

GU Cancers Symposium 2013 - Additional Noteworthy Research to be Presented at the 2013 Genitourinary Cancers Symposium February 14, 2013

GU Cancers Symposium 2013 - Active Surveillance- Intelligent PSA Testing February 14, 2013

GU Cancers Symposium 2013 - Improving active surveillance: The emerging role of biomarkers February 14, 2013

GU Cancers Symposium 2013 - The pathology perspective on available tools for active surveillance February 14, 2013

GU Cancers Symposium 2013 - The imaging perspective on available tools for active surveillance February 14, 2013

GU Cancers Symposium 2013 - Hospital readmission following cystectomy is associated with omission of post-operative chemotherapy in patients with urothelial carcinoma of the bladder - Overview by Marc Smaldone, MD, Fox Chase Cancer Center, PA February 14, 2013

Page 485 of 507